Avoid Fresenius Kabi: Ashwani Gujral

Ashwani Gujral, Chief Market Strategist, ashwanigujral.com, in a chat with ET Now, gives his views on some of the stocks


Wockhardt, Fresenius Kabi, Jubilant Life Sciences smaller stocks may be not too hefty on volumes but still making news today?

Wockhardt has been moving sideways or rather consolidating at higher levels. Once we can maintain these levels of Rs 405 I think another 70-80 bucks are possible on Wockhardt right up to Rs 475-480. On the other hand smaller stocks are likely to move higher in both pharma and FMCG. Jubilant Life Sciences has found support at lower levels and chances are that you could see 5% to 8% rallies on Jubilant. Fresenius Kabi is probably a low volume stock that you should avoid but clearly action is likely to shift in the smaller stocks in terms of pharma and FMCG. Wockhardt and all these other stocks would make good bias in case the market remains range.